522 related articles for article (PubMed ID: 24713205)
1. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes.
Lopez-Siles M; Martinez-Medina M; Busquets D; Sabat-Mir M; Duncan SH; Flint HJ; Aldeguer X; Garcia-Gil LJ
Int J Med Microbiol; 2014 May; 304(3-4):464-75. PubMed ID: 24713205
[TBL] [Abstract][Full Text] [Related]
2. Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer.
Lopez-Siles M; Martinez-Medina M; Surís-Valls R; Aldeguer X; Sabat-Mir M; Duncan SH; Flint HJ; Garcia-Gil LJ
Inflamm Bowel Dis; 2016 Jan; 22(1):28-41. PubMed ID: 26595550
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the Abundance and Co-occurrence of
Lopez-Siles M; Enrich-Capó N; Aldeguer X; Sabat-Mir M; Duncan SH; Garcia-Gil LJ; Martinez-Medina M
Front Cell Infect Microbiol; 2018; 8():281. PubMed ID: 30245977
[No Abstract] [Full Text] [Related]
4. Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa.
Eppinga H; Sperna Weiland CJ; Thio HB; van der Woude CJ; Nijsten TE; Peppelenbosch MP; Konstantinov SR
J Crohns Colitis; 2016 Sep; 10(9):1067-75. PubMed ID: 26971052
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification.
Lopez-Siles M; Aldeguer X; Sabat-Mir M; Serra-Pagès M; Duncan SH; Flint HJ; Garcia-Gil LJ; Martinez-Medina M
World J Gastrointest Pathophysiol; 2020 May; 11(3):64-77. PubMed ID: 32435523
[TBL] [Abstract][Full Text] [Related]
6. Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease.
Lopez-Siles M; Martinez-Medina M; Abellà C; Busquets D; Sabat-Mir M; Duncan SH; Aldeguer X; Flint HJ; Garcia-Gil LJ
Appl Environ Microbiol; 2015 Nov; 81(21):7582-92. PubMed ID: 26296733
[TBL] [Abstract][Full Text] [Related]
7. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.
Varela E; Manichanh C; Gallart M; Torrejón A; Borruel N; Casellas F; Guarner F; Antolin M
Aliment Pharmacol Ther; 2013 Jul; 38(2):151-61. PubMed ID: 23725320
[TBL] [Abstract][Full Text] [Related]
8. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.
Hansen R; Russell RK; Reiff C; Louis P; McIntosh F; Berry SH; Mukhopadhya I; Bisset WM; Barclay AR; Bishop J; Flynn DM; McGrogan P; Loganathan S; Mahdi G; Flint HJ; El-Omar EM; Hold GL
Am J Gastroenterol; 2012 Dec; 107(12):1913-22. PubMed ID: 23044767
[TBL] [Abstract][Full Text] [Related]
9. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease.
Fujimoto T; Imaeda H; Takahashi K; Kasumi E; Bamba S; Fujiyama Y; Andoh A
J Gastroenterol Hepatol; 2013 Apr; 28(4):613-9. PubMed ID: 23216550
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease.
Zhao H; Xu H; Chen S; He J; Zhou Y; Nie Y
J Gastroenterol Hepatol; 2021 Feb; 36(2):320-328. PubMed ID: 32815163
[TBL] [Abstract][Full Text] [Related]
11. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
Machiels K; Joossens M; Sabino J; De Preter V; Arijs I; Eeckhaut V; Ballet V; Claes K; Van Immerseel F; Verbeke K; Ferrante M; Verhaegen J; Rutgeerts P; Vermeire S
Gut; 2014 Aug; 63(8):1275-83. PubMed ID: 24021287
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota differs between children with Inflammatory Bowel Disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis.
Knoll RL; Forslund K; Kultima JR; Meyer CU; Kullmer U; Sunagawa S; Bork P; Gehring S
Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G327-G339. PubMed ID: 28039159
[TBL] [Abstract][Full Text] [Related]
13. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
[TBL] [Abstract][Full Text] [Related]
14. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease?
Jia W; Whitehead RN; Griffiths L; Dawson C; Waring RH; Ramsden DB; Hunter JO; Cole JA
FEMS Microbiol Lett; 2010 Sep; 310(2):138-44. PubMed ID: 20695899
[TBL] [Abstract][Full Text] [Related]
15. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
[TBL] [Abstract][Full Text] [Related]
16. Microbiota in pediatric inflammatory bowel disease.
Schwiertz A; Jacobi M; Frick JS; Richter M; Rusch K; Köhler H
J Pediatr; 2010 Aug; 157(2):240-244.e1. PubMed ID: 20400104
[TBL] [Abstract][Full Text] [Related]
17. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
[TBL] [Abstract][Full Text] [Related]
18. Expression of CCR6 and CXCR6 by Gut-Derived CD4
Godefroy E; Alameddine J; Montassier E; Mathé J; Desfrançois-Noël J; Marec N; Bossard C; Jarry A; Bridonneau C; Le Roy A; Sarrabayrouse G; Kerdreux E; Bourreille A; Sokol H; Jotereau F; Altare F
Gastroenterology; 2018 Oct; 155(4):1205-1217. PubMed ID: 29981781
[TBL] [Abstract][Full Text] [Related]
19. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.
Wang W; Chen L; Zhou R; Wang X; Song L; Huang S; Wang G; Xia B
J Clin Microbiol; 2014 Feb; 52(2):398-406. PubMed ID: 24478468
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases.
Thomazini CM; Samegima DA; Rodrigues MA; Victoria CR; Rodrigues J
Int J Med Microbiol; 2011 Aug; 301(6):475-9. PubMed ID: 21616711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
